Stockreport

Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib

Oncternal Therapeutics, Inc.  (ONCT) 
Last oncternal therapeutics, inc. earnings: 8/8 04:01 pm Check Earnings Report
PDF SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company developing potential first-in-class pr [Read more]